Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Financing Activities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Cash from Financing Activities for 4 consecutive years, with $283.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 9464.63% to $283.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $291.5 million through Dec 2025, down 20.08% year-over-year, with the annual reading at $291.5 million for FY2025, 20.08% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $283.4 million at Centessa Pharmaceuticals, up from $3.4 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $283.4 million in Q4 2025, with the low at $12000.0 in Q2 2023.
  • Average Cash from Financing Activities over 4 years is $45.2 million, with a median of $3.1 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities soared 877508.33% in 2024, then tumbled 98.6% in 2025.
  • Over 4 years, Cash from Financing Activities stood at $89000.0 in 2022, then skyrocketed by 7047.19% to $6.4 million in 2023, then tumbled by 53.42% to $3.0 million in 2024, then surged by 9464.63% to $283.4 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $283.4 million, $3.4 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.